A Phase 2 Open-Label Study to Assess the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AKCEA-ANGPTL3-LRX (ISIS 703802) Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS)

Trial Profile

A Phase 2 Open-Label Study to Assess the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AKCEA-ANGPTL3-LRX (ISIS 703802) Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs IONIS ANGPTL3 LRx (Primary)
  • Indications Hyperlipoproteinaemia type I
  • Focus Therapeutic Use
  • Sponsors Ionis Pharmaceuticals
  • Most Recent Events

    • 06 Dec 2017 Status changed from not yet recruiting to recruiting.
    • 10 Aug 2017 New trial record
    • 08 Aug 2017 According to an Akcea Therapeutics media release, the company is planning to start this trial in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top